Valeant Agrees to Acquire Synergetics
02 September 2015 - 11:15PM
Dow Jones News
By Tess Stynes
Valeant Pharmaceuticals International Inc. agreed to acquire
precision surgical devices supplier Synergetics USA Inc. for at
least $166.2 million, in a deal that aims to boost Bausch &
Lomb's global presence in vitreoretinal surgery.
Under the deal, Valeant will launch a tender offer for
Synergetics stock in which Synergetics shareholders will receive
$6.50 a share in cash, a 48% premium to Tuesday's close.
Shareholders also would receive a rights to additional payments of
as much as $1 a share if certain milestones are reached after the
deal closes, which is expected in the fourth quarter.
Synergetics's board of directors has unanimously approved the
deal.
The move is the latest in a string of deals for Valeant, which
has used multibillion-dollar acquisitions of companies like Bausch
& Lomb, Medicis and Salix to build up portfolios of eye, skin
and stomach products.
Last month, Valeant agreed to pay $1 billion for Sprout
Pharmaceuticals Inc., the closely held company that just won
approval to sell the first drug that aims to boost a woman's
libido.
Synergetics shares closed at $4.39 on Tuesday and were halted
premarket.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 02, 2015 09:00 ET (13:00 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Apr 2024 to May 2024
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Bausch Health Cos (New York Stock Exchange): 0 recent articles
More Valeant Pharmaceuticals International News Articles